The Health Care Service and Florida Blue updated their policies to cover Exact Sciences‘ Cologuard.
CMS released an updated Evidence of Coverage notice for Medicare Advantage plans, requiring those plans to cover Exact Sciences‘ Cologuard sans out-of-pocket costs.
Protagonist Therapeutics – a company developing oral treatments for IBD – sold more shares than expected on Wed., Aug. 10, and raised $90 million in the process.
More articles on GI company news:
Valeant, Norgine partner for bowel-cleansing solution; EndoChoice’s Q2 net loss totals $24.7M: 3 GI company key notes
Takeda Pharmaceutical plans $725M R&D overhaul, FDA approves AbbVie’s VIEKIRA XR for HCV & more — 5 GI company key notes
Olympus under fire again, Exact Sciences’ Q2 2016 revenue totals $21.2M & more — 5 GI company key notes
